139 related articles for article (PubMed ID: 9391500)
21. Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.
Welker HA; Weidekamm E; Houwing N; de Chatel R
Pharmacology; 1998 Jun; 56(6):297-307. PubMed ID: 9654216
[TBL] [Abstract][Full Text] [Related]
22. Mibefradil: a selective T-type calcium antagonist.
Massie BM
Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
[TBL] [Abstract][Full Text] [Related]
23. Comparison of binding of 3H-desmethoxyverapamil and 3H-mibefradil in vascular smooth muscle and heart membranes. Possible binding of mibefradil to a site distinct from the phenylalkylamine-binding site.
Ratner EI; Bochkov VN; Tkachuk VA
Arzneimittelforschung; 1996 Oct; 46(10):953-5. PubMed ID: 8931886
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
Abernethy DR
Am J Cardiol; 1997 Aug; 80(4B):4C-11C. PubMed ID: 9286848
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs.
Skerjanec A; Tawfik S; Tam YK
J Pharmacol Exp Ther; 1996 Aug; 278(2):817-25. PubMed ID: 8768736
[TBL] [Abstract][Full Text] [Related]
26. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
Welker HA
J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
[TBL] [Abstract][Full Text] [Related]
27. [Introducing mibefradil--a new T-calcium channel blocker].
Internist (Berl); 1997 Dec; 38(12 Suppl Mibefradil):1-4. PubMed ID: 9437250
[No Abstract] [Full Text] [Related]
28. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
[TBL] [Abstract][Full Text] [Related]
29. What lessons can be learnt from withdrawal of mibefradil from the market?
Po AL; Zhang WY
Lancet; 1998 Jun; 351(9119):1829-30. PubMed ID: 9652662
[No Abstract] [Full Text] [Related]
30. Clinical pharmacokinetics of mibefradil.
Welker HA; Wiltshire H; Bullingham R
Clin Pharmacokinet; 1998 Dec; 35(6):405-23. PubMed ID: 9884814
[TBL] [Abstract][Full Text] [Related]
31. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
[TBL] [Abstract][Full Text] [Related]
32. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
[No Abstract] [Full Text] [Related]
33. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
[No Abstract] [Full Text] [Related]
34. Withdrawal of Posicor from market.
SoRelle R
Circulation; 1998 Sep; 98(9):831-2. PubMed ID: 9738634
[No Abstract] [Full Text] [Related]
35. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
[TBL] [Abstract][Full Text] [Related]
36. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun S; van der Wall EE; Emanuelsson H; Kobrin I
J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
[TBL] [Abstract][Full Text] [Related]
37. Mibefradil and an effective formulary system.
Vermeulen LC; Dunham DB
Am J Health Syst Pharm; 1998 Sep; 55(18):1934-5. PubMed ID: 9784776
[No Abstract] [Full Text] [Related]
38. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group.
Van der Vring JA; Cleophas TJ; Van der Wall EE; Niemeyer MG
Am J Ther; 1999 Jul; 6(4):229-33. PubMed ID: 11329102
[TBL] [Abstract][Full Text] [Related]
39. Mibefradil withdrawn from the market.
Billups SJ; Carter BL
Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
[No Abstract] [Full Text] [Related]
40. Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
Waeber B
Cardiology; 1998; 89 Suppl 1():16-22. PubMed ID: 9570425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
